In 2015, the Food and Drug Administration approved flibanserin (Addyi) as the first treatment for hypoactive sexual desire disorder
in premenopausal women.
These allowed claims under the patent Application Serial Number 14/704,223 cover methods of treating female sexual dysfunction and hypoactive sexual desire disorder
(HSDD) with bremelanotide, an investigational product designed for on-demand treatment of HSDD in premenopausal women.
Mechanism of action of flibanserin, a multifunctional serotonin agonist and antagonist (MSAA), in hypoactive sexual desire disorder
Hypoactive sexual desire disorder
(HSDD), a common sexual complaint affecting approximately 1 in 10 women in the USA, Europe and Australia, is a multifactorial and multifaceted disorder with biological, psychological and interpersonal relationships all being potential contributing factors.
A standardized diagnostic interview for hypoactive sexual desire disorder
in women: Standard operating procedure (SOP Part 2).
Depression occurred in 40 per cent of those with hypoactive sexual desire disorder
, she said.
The prevalence of hypoactive sexual desire disorder
in Colombian females and associated factors
The diagnostic criteria for Hypoactive Sexual Desire Disorder
(HSDD) outlined in the Diagnostic and Statistical Manual of Mental Disorders (DSM; American Psychiatric Association, 2000) have generated a great deal of discussion and controversy (Basson et al.
The Merck Manual estimates hypoactive sexual desire disorder
occurs in about 20 percent of women.
After discussion of the nature and causes of these problems, and issues and debates, a group of psychologists, psychiatrists, and sexual medicine specialists from the US and Canada address treatment of hypoactive sexual desire disorder
using a variety of therapies, such as cognitive-behavioral and mindfulness-based therapy, crucible therapy, and pharmacology, as well as the role of androgens, assessment, comorbid individual and relationship dysfunction, sexual desire after breast cancer, and other topics.
A discussion of sexual dysfunction at this end of the continuum and cases of Hypoactive Sexual Desire Disorder
and Vaginismus demonstrate the clinical effectiveness of an approach combining hypnosis and ego-state therapy to facilitate healthy adaptive differentiation.
for treating women with hypoactive sexual desire disorder